Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui